EYPT

SEC source: 0001562180-25-000226 · primarydocument.xml · derivative · entry 6

Duker Jay S. · CIK 0001630864 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 228,334

Underlying: Common Stock · 195,000 shares

Expires not disclosed

F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 3, 2026.

F3 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 3, 2026.

SEC source: 0001562180-24-006671 · primarydocument.xml · derivative · entry 1

Hassan Fred · CIK 0001110744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2034-09-03

F1 · derivative.exercise_date: The option becomes exercisable in three ratable annual installments beginning on September 3, 2025.

SEC source: 0001562180-24-006432 · primarydocument.xml · nonDerivative · entry 1

ANDO GORAN · CIK 0001110748 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,150

SEC source: 0001562180-24-006440 · primarydocument.xml · nonDerivative · entry 1

DICICCO WENDY F · CIK 0001225165 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,967

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.77 to $7.81. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-006431 · primarydocument.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,500

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $8.13. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-006378 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,635

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.87 to $7.88. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 10

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 16,666

Underlying: Common Stock · 16,666 shares

Expires 2033-07-10

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 9

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 16,666 shares

Expires 2033-07-10

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F7 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until July 10, 2027.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 8

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 169,050

Underlying: Common Stock · 56,350 shares

Expires 2033-01-05

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F6 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 7

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,750

Underlying: Common Stock · 56,350 shares

Expires 2033-01-05

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F6 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until January 6, 2027.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 6

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 145,000

Underlying: Common Stock · 30,000 shares

Expires 2032-02-09

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 5

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 30,000 shares

Expires 2032-02-09

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F5 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2026.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 4

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 182,535

Underlying: Common Stock · 26,713 shares

Expires 2031-02-09

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F4 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,165

Underlying: Common Stock · 26,713 shares

Expires 2031-02-09

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F4 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full. The remaining portion of the option retained by the reporting person continues to vest on a monthly basis until February 9, 2025.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 2

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Family Trust

Disclosed balance after: 74,800

Underlying: Common Stock · 1,558 shares

Expires 2030-02-28

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full.

F3 · ownership.nature: These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-24-005854 · primarydocument.xml · derivative · entry 1

Lurker Nancy · CIK 0001450485 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,558 shares

Expires 2030-02-28

F1 · kind: On July 26, 2024, the reporting person transferred the vested portion of an option to purchase common stock, par value $0.001 per share ("Common Stock"), of EyePoint Pharmaceuticals, Inc. (the "Company"), to an irrevocable family trust of which the reporting person's spouse is trustee and of which the reporting person's immediate family members are the sole beneficiaries (the "Family Trust").

F2 · derivative.exercise_date: The option to purchase will vest and become exercisable over a four year period as follows: 25% at the one year anniversary of grant and then ratably over the remaining thirty-six months. At the time of the transfer, the portion of the option that was transferred to the Family Trust vested in full.

SEC source: 0001562180-24-005752 · primarydocument.xml · derivative · entry 5

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,525

Underlying: Common Stock · 6,525 shares

Expires 2033-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-005752 · primarydocument.xml · derivative · entry 4

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,250

Underlying: Common Stock · 3,250 shares

Expires 2033-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-005752 · primarydocument.xml · nonDerivative · entry 3

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,850

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.125. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-005752 · primarydocument.xml · nonDerivative · entry 2

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,475

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-005752 · primarydocument.xml · nonDerivative · entry 1

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-005698 · primarydocument.xml · derivative · entry 2

Zaderej Karen L. · CIK 0001530968 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning July 11, 2023.

F1 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning July 11, 2023.

SEC source: 0001562180-24-005698 · primarydocument.xml · nonDerivative · entry 1

Zaderej Karen L. · CIK 0001530968 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-005700 · primarydocument.xml · derivative · entry 3

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,223

Underlying: Common Stock · 11,111 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024.

F2 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024.

SEC source: 0001562180-24-005700 · primarydocument.xml · nonDerivative · entry 1

Lurker Nancy · CIK 0001450485 · Director · Executive Vice Chair

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,462

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-005701 · primarydocument.xml · derivative · entry 4

Duker Jay S. · CIK 0001630864 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,334

Underlying: Common Stock · 16,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024.

F3 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning July 10, 2024.

SEC source: 0001562180-24-005701 · primarydocument.xml · nonDerivative · entry 2

Duker Jay S. · CIK 0001630864 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,027

F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units

SEC source: 0001562180-24-005701 · primarydocument.xml · nonDerivative · entry 1

Duker Jay S. · CIK 0001630864 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,086

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-005299 · primarydocument.xml · derivative · entry 2

ADAMIS ANTHONY P · CIK 0001277479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units vests in three ratable annual installments beginning June 23, 2023.

F1 · derivative.expiration_date: The restricted stock units vests in three ratable annual installments beginning June 23, 2023.

SEC source: 0001562180-24-005299 · primarydocument.xml · nonDerivative · entry 1

ADAMIS ANTHONY P · CIK 0001277479 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004638 · primarydocument.xml · derivative · entry 5

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,050

Underlying: Common Stock · 6,525 shares

Expires 2033-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004638 · primarydocument.xml · derivative · entry 4

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,500

Underlying: Common Stock · 3,250 shares

Expires 2033-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004638 · primarydocument.xml · nonDerivative · entry 3

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,700

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.00 to $10.87. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-004638 · primarydocument.xml · nonDerivative · entry 2

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,325

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004638 · primarydocument.xml · nonDerivative · entry 1

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,075

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004462 · primarydocument.xml · derivative · entry 3

Elston George · CIK 0001429932 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 7,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units vest in three ratable annual installments beginning May 25, 2024.

F2 · derivative.expiration_date: The restricted stock units vest in three ratable annual installments beginning May 25, 2024.

SEC source: 0001562180-24-004462 · primarydocument.xml · nonDerivative · entry 2

Elston George · CIK 0001429932 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,480

F1 · kind: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.

SEC source: 0001562180-24-004462 · primarydocument.xml · nonDerivative · entry 1

Elston George · CIK 0001429932 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,107

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004106 · primarydocument.xml · derivative · entry 5

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,575

Underlying: Common Stock · 6,525 shares

Expires 2033-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004106 · primarydocument.xml · derivative · entry 4

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,750

Underlying: Common Stock · 3,250 shares

Expires 2033-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004106 · primarydocument.xml · nonDerivative · entry 3

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,550

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.44 to $12.83. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001562180-24-004106 · primarydocument.xml · nonDerivative · entry 2

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,175

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-004106 · primarydocument.xml · nonDerivative · entry 1

GUYER DAVID R · CIK 0001277476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,925

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000929638-24-001743 · form4.xml · nonDerivative · entry 2

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 8,325,000

F3 · price: Represents the weighted average sale right of the shares purchased in a series of open market transactions on the transaction date at prices ranging from $12.08 to $12.95 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-001743 · form4.xml · nonDerivative · entry 1

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 8,117,847

F2 · price: Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $11.08 to $12.07 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the "SEC"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-001536 · form4.xml · nonDerivative · entry 2

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 7,475,000

F3 · price: Represents the weighted average sale right of the shares purchased in a series of open market transactions on the transaction date at prices ranging from $18.43 to $19.06 per share. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0000929638-24-001536 · form4.xml · nonDerivative · entry 1

Cormorant Asset Management, LP · CIK 0001583977 · 10% owner

Chen Bihua · CIK 0001599214 · 10% owner

Cormorant Global Healthcare Master Fund, LP · CIK 0001618442 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 7,288,479

F2 · price: Represents the weighted average sale price of Common Stock (the "shares") purchased in a series of open market transactions on the transaction date at prices ranging from $17.36 to $18.25 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission (the "SEC"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price. All of the shares reported herein were purchased by the Master Fund.

F1 · ownership.nature: Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of Cormorant Global Healthcare Master Fund, LP (the "Master Fund"). Cormorant Global Healthcare GP, LLC ("GP LLC") serves as General Partner of the Master Fund. Bihua Chen serves as manager of Cormorant, GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

SEC source: 0001562180-24-003193 · primarydocument.xml · derivative · entry 9

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.

F4 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.

SEC source: 0001562180-24-003193 · primarydocument.xml · derivative · entry 8

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,834 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.

F3 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.

SEC source: 0001562180-24-003193 · primarydocument.xml · derivative · entry 7

Paggiarino Dario A. · CIK 0001574261 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,570 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.

F2 · derivative.expiration_date: The restricted stock units will vest in three ratable annual installments beginning January 6, 2024.